Posts

Garijo’s Plan to Revamp Sanofi: R&D Cleanup, More M&A, and a China Push Explained

on

Relation Deepens GSK AI Pact With Up to $110M Deal Aiming at Transformationally Different Success Rates in Drug Discovery

on

AbbVie's $10.9B Move for Apogee's Long-Acting I&I Drug Candidates

on

Helmed by Sanofi vet, Bionyra emerges with $165M and three licensed I&I assets

on

Biogen acquires RayThera in up to $1B deal to bolster preclinical immunology pipeline

on

Roche Launches Up to $2.3B Blood‑Cancer Bet Around Nurix’s BTK Degrader Bexobrutideg

on

Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth

on

Biogen Pursues Early-Stage Assets to Build Next Generation Growth Pipeline

on

Biogen's Post-Apellis Strategy: Expanding Early-Stage Pipeline to Drive Next-Generation Growth

on

AbbVie Reports Strong Skyrizi Sales Amid Wall Street Concerns Over J&J's Icotyde Pill

on

Sanofi Defends Belén Garijo's CEO Appointment Amid R&D and Immunology Focus

on

Bristol Myers Squibb and Bain Capital Launch New Autoimmune Disease Biotech Company

on

Biogen Acquires Apellis for $5.6 Billion to Expand Immunology and Kidney Disease Portfolio

on

Pinnacle Medicines Secures $89M Series B Funding for Oral Peptide Pipeline

on

GSK Acquires RAPT Therapeutics for $2.2 Billion to Advance Food Allergy Drug Ozureprubart

on

Relation and Deerfield form NewCos to develop drugs from AI-discovered targets

on

Harbour BioMed inks $90M upfront, $1B+ antibody alliance with Bristol Myers Squibb

on

Sanofi returns to Dren Bio for another B‑cell depletion therapy with $100M upfront

on

Regeneron and ModeX Forge Potential $1 Billion+ Collaboration to Develop Multispecific Antibody Drugs

on

Regeneron and ModeX Forge Potential $1 Billion+ Collaboration to Develop Multispecific Antibody Drugs

on